# Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

> **NCT00643604** · PHASE4 · TERMINATED · sponsor: **United Therapeutics** · enrollment: 7 (actual)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** treprostinil sodium

## Key facts

- **NCT ID:** NCT00643604
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03
- **Primary completion:** 2010-01
- **Final completion:** 2012-02
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Due to availability of eligible subjects at center and enrollment competition with other studies.
- **Last updated:** 2024-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00643604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00643604, "Rapid Switch From Flolan to Remodulin in the Outpatient Clinic". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00643604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*